Company intelligence / Profile preview

Carus

Dundee, Scotland, United Kingdom

Ownership: Private
Development stage: Other

Overview

Carus Therapeutics was a biotechnology company primarily focused on the development of novel treatments for Rett Syndrome, a rare genetic neurological disorder. The company's research centered on identifying and developing small molecule activators of the MECP2 protein, which is deficient or dysfunctional in patients with the condition. Spun out from academic research at the University of Dundee, Carus aimed to address the underlying genetic cause of Rett Syndrome rather than just managing symptoms. Despite its specialized focus and support from patient advocacy groups, the company was dissolved in early 2021.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Rett Syndrome Research Trust (RSRT)

Beyond the preview

Go deeper on Carus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Carus.

Explore the full profile